Arylamine N-acetyltransferase Aggregation and Constitutive Ubiquitylation

Journal of Molecular Biology

Volumn 361, Issue 3, 2006, Pages 482-492

  Liu, Fen ^a   Zhang, Naixia ^a   Zhou, Xin ^a   Hanna, Patrick E ^a   Wagner, Carston R ^a   Koepp, Deanna M ^a   Walters, Kylie J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

arylamine N acetyltransferase; polymorphism; protein aggregation; protein degradation; ubiquitylation

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; TRYPTOPHAN;

ACETYLATION; ARTICLE; CATALYSIS; CELL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; GENETIC POLYMORPHISM; HAMSTER; HUMAN; KINETICS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; STEADY STATE; SUBSTITUTION REACTION; THERMOSTABILITY; UBIQUITINATION;

CRICETINAE;

EID: 33746355247     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.06.029     Document Type: Article

References (36)

1. Riddle B., and Jencks W.P. Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. J. Biol. Chem. 246 (1971) 3250-3258
2. Weber W.W., and Hein D.W. N-acetylation pharmacogenetics. Pharmacol. Rev. 37 (1985) 25-79
3. Evans D.A. N-acetyltransferase. Pharmacol. Ther. 42 (1989) 157-234
4. Hughes H.B. On the metabolic fate of isoniazid. J. Pharmacol. Exp. Ther. 109 (1953) 444-452
5. Minchin R.F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J. 307 (1995) 1-3
6. Upton A., Smelt V., Mushtaq A., Aplin R., Johnson N., Mardon H., and Sim E. Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy. Biochim. Biophys. Acta 1524 (2000) 143-148
7. Hein D.W., Rustan T.D., Doll M.A., Bucher K.D., Ferguson R.J., Feng Y., et al. Acetyltransferases and susceptibility to chemicals. Toxicol. Letters 64-65 (1992) 123-130 (Spec No)
8. Vineis P., Bartsch H., Caporaso N., Harrington A.M., Kadlubar F.F., Landi M.T., et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369 (1994) 154-156
9. Hanna P.E. N-acetyltransferases, O-acetyltransferases, and N,O-acetyltransferases: enzymology and bioactivation. Advan. Pharmacol. 27 (1994) 401-430
10. Garcia-Closas M., Malats N., Silverman D., Dosemeci M., Kogevinas M., Hein D.W., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 (2005) 649-659
11. Yu M.C., Skipper P.L., Taghizadeh K., Tannenbaum S.R., Chan K.K., Henderson B.E., and Ross R.K. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J. Natl. Cancer Inst. 86 (1994) 712-716
12. Snyderwine E.G., Wirth P.J., Roller P.P., Adamson R.H., Sato S., and Thorgeirsson S.S. Mutagenicity and in vitro covalent DNA binding of 2-hydroxyamino-3-methylimidazolo[4,5-f]quinoline. Carcinogenesis 9 (1988) 411-418
13. Snyderwine E.G., Davis C.D., Nouso K., Roller P.P., and Schut H.A. 32P-postlabeling analysis of IQ, MeIQx and PhIP adducts formed in vitro in DNA and polynucleotides and found in vivo in hepatic DNA from IQ-, MeIQx- and PhIP-treated monkeys. Carcinogenesis 14 (1993) 1389-1395
14. Oda Y., Yamazaki H., Watanabe M., Nohmi T., and Shimada T. Development of high sensitive umu test system: rapid detection of genotoxicity of promutagenic aromatic amines by Salmonella typhimurium strain NM2009 possessing high O-acetyltransferase activity. Mutat. Res. 334 (1995) 145-156
15. Lower Jr. G.M., Nilsson T., Nelson C.E., Wolf H., Gamsky T.E., and Bryan G.T. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 29 (1979) 71-79
16. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 29-42
17. Brockmoller J., Cascorbi I., Kerb R., and Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56 (1996) 3915-3925
18. Okkels H., Sigsgaard T., Wolf H., and Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 225-231
19. Filiadis I.F., Georgiou I., Alamanos Y., Kranas V., Giannakopoulos X., and Lolis D. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J. Urol. 161 (1999) 1672-1675
20. Gu J., Liang D., Wang Y., Lu C., and Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat. Res. 581 (2005) 97-104
21. Hein D.W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507 (2002) 65-77
22. Butcher N.J., Arulpragasam A., and Minchin R.F. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J. Biol. Chem. 279 (2004) 22131-22137
23. Sinclair J.C., Sandy J., Delgoda R., Sim E., and Noble M.E. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nature Struct. Biol. 7 (2000) 560-564
24. Sandy J., Mushtaq A., Kawamura A., Sinclair J., Sim E., and Noble M. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis: an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 318 (2002) 1071-1083
25. Wang H., Vath G.M., Kawamura A., Bates C.A., Sim E., Hanna P.E., and Wagner C.R. Overexpression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. 24 (2005) 65-75
26. Wang H., Liu L., Hanna P.E., and Wagner C.R. The catalytic mechanism of hamster arylamine N-acetyltransferase 2. Biochemistry 44 (2005) 11295-11306
27. Sticha K.R., Sieg C.A., Bergstrom C.P., Hanna P.E., and Wagner C.R. Overexpression and large-scale purification of recombinant hamster polymorphic arylamine N-acetyltransferase as a dihydrofolate reductase fusion protein. Protein Expr. Purif. 10 (1997) 141-153
28. Treier M., Staszewski L.M., and Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78 (1994) 787-798
29. Matsuo H., Walters K., Teruya K., Tanaka T., Gassner G., Lippard S.J., et al. Identification by NMR spectroscopy of residues at contact surfaces in large, slowly exchanging macromolecular complexes. J. Am. Chem. Soc. 121 (1999) 9903-9904
30. Kawamura A., Graham J., Mushtaq A., Tsiftsoglou S.A., Vath G.M., Hanna P.E., et al. Eukaryotic arylamine N-acetyltransferase investigation of substrate specificity by high-throughput screening. Biochem. Pharmacol. 69 (2005) 347-359
31. Simons K.T., Bonneau R., Ruczinski I., and Baker D. Ab initio protein structure prediction of CASP III targets using ROSETTA. Proteins: Struct. Funct. Genet. Suppl. 3 (1999) 171-176
32. Zang Y., Zhao S., Doll M.A., States J.C., and Hein D.W. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 14 (2004) 717-723
33. Meusser B., Hirsch C., Jarosch E., and Sommer T. ERAD: the long road to destruction. Nature Cell Biol. 7 (2005) 766-772
34. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 426 (2003) 895-899
35. Sticha K.R., Bergstrom C.P., Wagner C.R., and Hanna P.E. Characterization of hamster recombinant monomorphic and polymorphic arylamine N-acetyltransferases: bioactivation and mechanism-based inactivation studies with N-hydroxy-2-acetylaminofluorene. Biochem. Pharmacol. 56 (1998) 47-59
36. Wang H., Vath G.M., Gleason K.J., Hanna P.E., and Wagner C.R. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies. Biochemistry 43 (2004) 8234-8246